ArticleEuropean urology open science2026
Prostate Cancer Risk and DNA Mismatch Repair Deficiency Among Lynch Syndrome Patients.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.European radiology · 2026Article
- Understanding the utilization of genetic counseling and testing among patients with prostate cancer.The Canadian journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Lynch syndrome (LS) increases the risk of gastrointestinal, endometrial, and other cancers. Recent data suggest that LS also increases the risk of prostate cancer (PC). Our study aims to characterize the incidence and the clinical and molecular features of PC in LS. Methods: Adult males with LS were identified from an institutional genetic testing registry. PC diagnoses were identified, and tumor tissue was assessed for DNA mismatch repair deficiency (dMMR) by immunohistochemistry. Key findings and limitations: Among 235 adult males with LS, 35 were diagnosed with PC at a median age of 60 yr (interquartile range: 58-69.5). By age 75 yr, the cumulative incidence of any PC and clinically significant PC was 38% (95% confidence interval [CI]: 27-50%) and 26% (95% CI: 16-37%), respectively. MMR deficiency was observed in 75% of tumors from Conclusions and clinical implications: MMR-deficient PC was significantly associated with higher-risk clinicopathological features, suggesting that MMR testing should be considered for LS patients with PC to help inform clinical management. Additionally, these data support special consideration of PC screening among LS patients with Patient summary: In this study, we looked at the incidence and characteristics of prostate cancer that develops among individuals with Lynch syndrome. We found that individuals with Lynch syndrome have an elevated risk of developing prostate cancer, but this risk varied by Lynch syndrome gene and family history. This information will help guide targeted prostate cancer screening and management for individuals with Lynch syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.